Catalog No.: PC-47067Not For Human Use, Lab Use Only.
RI173 is a potent, covalent, triple-acting inhibitor of SARS-CoV-2 protease Mpro, PLpro and human cathepsin L with IC50 of 0.6 uM, 0.2 uM and 1.7 uM, respectively.
RI173 is a potent, covalent, triple-acting inhibitor of SARS-CoV-2 protease Mpro, PLpro and human cathepsin L with IC50 of 0.6 uM, 0.2 uM and 1.7 uM, respectively.
RI173 covalently reacts to the active cysteine residue of SARS-CoV-2 Mpro (Cys 145) and Plpro (Cys111), exhibits 10-fold more potent than disulfiram against SARS-CoV-2 protease.
RI173 exhibits antiviral activity in a narrow range from approximately 100 to 200 nM in SARS-CoV-2 infectivity cells-based assays。
RI173 also shows greater antiviral effect and less toxicitythan disulfiram.
Physicochemical Properties
M.Wt
324.490
Formula
C10H16N2O2S4
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
morpholine-4-carbothioic dithioperoxyanhydride
References
1. Meewan I, et al. Pharmaceuticals (Basel). 2022 Jun 13;15(6):744.
